Advertise with us
[September 02, 2014]
B-Cell Non-Hodgkin's Lymphoma Treatment Market Value to Reach $5.4 Billion by 2018, Reveals New Report
(ReleaseWire Via Acquire Media NewsEdge) Market Research Reports, Inc. has announced the addition of “OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018” research report to their website
DE -- (ReleaseWire) -- 09/02/2014 -- The B-cell non-Hodgkin’s Lymphoma (NHL) treatment market value will experience moderate growth across six major markets (the US, France, Italy, Germany, Spain and the UK), from $4.59 billion in 2013 to $5.41 billion by 2018, according to research.
The company’s OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 report states that the global NHL treatment paradigm will undergo a dramatic shift away from chemoimmunotherapy regimens with the launch of targeted B-cell receptor inhibitors, Imbruvica (ibrutinib) and Zydelig (idelalisib), in the relapsed/refractory setting across multiple indications.
Senior Analyst covering Oncology and Hematology, says: “The US Food and Drug Administration gave the green light to Imbruvica for use in Rituxan-refractory mantle cell lymphoma (MCL) patients in November 2013. Meanwhile, Zydelig recently received approval for the treatment of relapsed/refractory follicular lymphoma patients who have received at least two prior therapies.
“Imbruvica has set the bar for pricing in the NHL market with an annual cost of therapy (ACOT) calculated at approximately $133,000. On the other hand, Zydelig will be priced very competitively, at an average ACOT of around $87,000, in anticipation of its future combination with Roche’s Rituxan.” The forecasts that Zydelig will emerge as the overall NHL treatment revenue leader across all indications, with total sales reaching $888 million in 2018. This will be primarily due to Imbruvica’s smaller target patient population, as MCL comprises approximately 6% of all NHL diagnoses only.
Senior Analyst Continue: “From 2017, we anticipate that Zydelig will also be utilized in combination with Rituxan, and the potential to combine with the gold-standard backbone therapy will further drive the drug’s uptake in this setting.
“However, both Zydelig and Imbruvica’s opportunities for premium pricing will be limited in cost-conscious European countries, and this will limit revenue growth in these markets despite the strong uptake among patients.” Publisher predicts that the NHL treatment market in the five European countries will shrink from $1.66 billion to $1.53 billion over the forecast period, caused by authorities’ pricing limitations, as well as competition from generic bendamustine and biosimilar rituximab, beginning in 2014 and 2018, respectively.
OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018 report provides information on annualized B-cell non-Hodgkin’s Lymphoma (NHL) therapeutics market revenue, annual cost of therapy and patient share in the first-line and relapsed/refractory setting, forecast from 2013 to 2018 across six major markets (the US, France, Italy, Germany, Spain and the UK). Key topics covered include pipeline analysis, strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the B-cell NHL therapeutics market. Browse this report –
Other Reports: 1st - Acute Heart Failure Global Clinical Trials Review, H2, 2014 - visit at:
2nd - Arterial Calcification Global Clinical Trials Review, H2, 2014 - visit at:
3rd - Bacterial Endocarditis Global Clinical Trials Review, H2, 2014 - visit at:
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
For regular industry updates subscribe to our newsletter at:
more information on this press release visit:
Relations ContactAmitava SenVP - Sales & MarketingMarket Research Reports, IncTelephone: 302-703-7787Email: Click to Email Amitava SenWeb:
Back To NFVZone's Homepage